LIF and myeloid sarcoma: This study confirms that the CNTF/LIF signalling pathway is an attractive neuroprotective therapeutic target for MS; and that LIF therapy could be useful as an adjunct to conventional immuno-modulatory or immune-cell trafficking inhibitory therapies.